Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00121108 · ClinicalTrials.gov registry record · Phase 3
MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States
A Phase 3 study of Healthy, sponsored by MedImmune.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,127
- Enrollment target
- 12
- Study locations
NCT00121108 is a Phase 3 study of Healthy that has completed, run by MedImmune. The registered enrollment target is 2,127 participants, above the 645-participant average among 1,090 other Healthy trials with a reported enrollment target (230% higher). The trial reports 12 study locations across 3 states.
The verdict
NCT00121108, a Phase 3 study of Healthy, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,127 participants
- Enrollment target
- 12
- Study locations
Study Summary
MI-CP117 was a Phase 3, randomized, double-blind, placebo-controlled trial designed to determine if motavizumab is more effective than placebo in reducing RSV hospitalization in otherwise healthy Native American Infants in the Southwestern United States during their first RSV season.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Motavizumab
Study Locations (12)
Arizona
- Research Site - Chinle
- Research Site - Cibecue
- Research Site - Fort Definace
- Research Site - San Carlos
- Research Site - Tuba City
- Research Site - Whiteriver
- Research Site - Winslow
New Mexico
- Research Site - Bloomfield
- Research Site - Crownpoint
- Research Site - Gallup
- Research Site - Shiprock
Maryland
- Research Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,127 participants |
| Start Date | 2004-11-15 |
| Est. Completion | 2010-12-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00121108
The ClinicalTrials.gov registry entry for NCT00121108 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,127 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 645-participant average among 1,090 other Healthy trials with a reported enrollment target (230% higher). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00121108 reports 12 study locations spanning 3 distinct geographic areas - top geographies include Arizona, New Mexico, Maryland.
Frequently Asked Questions
What is clinical trial NCT00121108 about?
NCT00121108 is a clinical study titled "MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States". MI-CP117 was a Phase 3, randomized, double-blind, placebo-controlled trial designed to determine if motavizumab is more effective than placebo in reducing RSV hospitalization in otherwise healthy Native American Infants in the Southwestern United States during their first RSV season.
What is the current status of trial NCT00121108?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,127 participants. The study started on 2004-11-15. Estimated completion is 2010-12-27.
What conditions does trial NCT00121108 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT00121108?
The interventions under investigation include: Placebo (OTHER), Motavizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00121108?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00121108 being conducted?
This trial has 12 study locations across Arizona, Maryland, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
RECRUITING · Phase 3
-
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
RECRUITING · Phase 3
-
Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
COMPLETED · Phase 3
-
A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics
COMPLETED · Phase 3
-
Study to Investigate the Potential of Probiotics in Yogurt
COMPLETED · Phase 3
-
Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.